Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Top Cited Papers
Open Access
- 16 July 2025
- journal article
- research article
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (8) , 1610-1621
Abstract
Tau positron emission tomography (PET) imaging allows in vivo detection of tau proteinopathy in Alzheimer’s disease, which is associated with neurodegeneration and cognitive decline. Understanding how demographic, clinical and genetic factors relate to tau PET positivity will facilitate its use for clinical practice and research. Here we conducted an analysis of 42 cohorts worldwide (N = 12,048), including 7,394 cognitively unimpaired (CU) participants, 2,177 participants with mild cognitive impairment (MCI) and 2,477 participants with dementia. We found that from age 60 years to 80 years, tau PET positivity in a temporal composite region increased from 1.1% to 4.4% among CU amyloid-β (Aβ)-negative participants and from 17.4% to 22.2% among CU Aβ-positive participants. Across the same age span, tau PET positivity decreased from 68.0% to 52.9% in participants with MCI and from 91.5% to 74.6% in participants with dementia. Age, Aβ status, APOE ε4 carriership and female sex were all associated with a higher prevalence of tau PET positivity across groups. APOE ε4 carriership in CU individuals lowered the age at onset of both Aβ positivity and tau positivity by decades. Finally, we replicated these associations in an independent autopsy dataset (N = 5,072 from 3 cohorts).Keywords
This publication has 70 references indexed in Scilit:
- Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareJAMA, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older AdultsJAMA Neurology, 2020
- Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic ChangesJAMA Neurology, 2020
- Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older AdultsJAMA Neurology, 2019
- Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2018
- Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal PersonsJAMA, 2017
- Prevalence of Cerebral Amyloid Pathology in Persons Without DementiaJAMA, 2015
- Prevalence of Amyloid PET Positivity in Dementia SyndromesJAMA, 2015
- Sex Differences in the Clinical Manifestations of Alzheimer Disease PathologyArchives of General Psychiatry, 2005